title: Fourth International Conference: Modern Vaccines/Adjuvants Formulation--Impact on Future Development: May 15-17 2013, CHUV, Lausanne, Switzerland.
abstract: On the 15-17th of May 2013, about 120 scientists, postdoctoral fellows and professors representing renowned academic institutes and senior scientists and executives from small biotechs, contract research organizations (CROs) and Big Pharma companies, gathered at the Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, Switzerland for the 4th international conference on Modern Vaccines and Adjuvants Formulation. Despite this relative small number, the speakers and attendees covered together a very broad field of expertise. Indeed, experts in microbiology, immunology, biochemistry, formulation, virus and nanoparticle characterization, vaccine production, quality control as well as regulatory professionals attended the conference and were able to present their works and discuss new developments within the field of vaccine and adjuvant development, characterization and approval process. This broad diversity was a highpoint of the conference and allowed for a stimulating environment and underlined the complexity of the challenges that the field currently faces in order to develop better or completely new vaccines and adjuvants.
authors.affiliation: Account Manager/Scientific Advisor; Vironova AB; Stockholm, Sweden.
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Tupin
mesh_terms: D000276:Adjuvants, Immunologic / Q000737:chemistry / Q000302:isolation & purification*; D002626:Chemistry, Pharmaceutical / Q000379:methods* / Q000639:trends*; D055808:Drug Discovery / Q000379:methods* / Q000639:trends*; D006801:Humans; D013557:Switzerland; D014612:Vaccines / Q000737:chemistry / Q000276:immunology* / Q000302:isolation & purification*
chemical_list: D000276:Adjuvants, Immunologic; D014612:Vaccines
keywords: Immunostimulatory complexe (ISCOM); Nanoemulsion (nanoE); Nanoparticle (NP); adjuvant; vaccine
references.citation: J Infect Dis. 2012 Jul 15;206(2):158-66
references.pmid: 22551811
references.citation: Vaccine. 2003 Sep 8;21(25-26):3801-14
references.pmid: 12922114
references.citation: PLoS One. 2008 Aug 13;3(8):e2954
references.pmid: 18698426
references.citation: Vaccine. 2009 Jul 16;27(33):4388-401
references.pmid: 19450632
references.citation: Vaccine. 2011 Jan 17;29(4):804-12
references.pmid: 21094269
references.citation: J Infect Dis. 2013 Aug 1;208(3):385-93
references.pmid: 23785124
references.citation: Crit Rev Immunol. 2010;30(2):189-99
references.pmid: 20370629
references.citation: PLoS One. 2011;6(7):e21823
references.pmid: 21789184
references.citation: Vaccine. 2010 Nov 23;28(50):7897-906
references.pmid: 20934457
references.citation: Nat Rev Immunol. 2011 Nov 04;11(12):865-72
references.pmid: 22051890
references.citation: Vaccine. 2013 Mar 25;31(13):1725-33
references.pmid: 23384754
references.citation: Proc Natl Acad Sci U S A. 2011 Nov 1;108(44):E989-97
references.pmid: 21969597
references.citation: Vaccine. 2011 Oct 19;29(45):8049-59
references.pmid: 21864624
references.citation: Vaccine. 2011 Sep 16;29(40):6959-66
references.pmid: 21787826
references.citation: Clin Vaccine Immunol. 2008 Feb;15(2):348-58
references.pmid: 18057181
references.citation: Nat Rev Microbiol. 2005 Aug;3(8):656-62
references.pmid: 16012514
references.citation: AIDS Res Hum Retroviruses. 2008 Feb;24(2):271-81
references.pmid: 18260780
references.citation: Infect Immun. 2007 Aug;75(8):4020-9
references.pmid: 17502384
references.citation: PLoS One. 2012;7(7):e41451
references.pmid: 22844480